The FDA granted the approval of Amtagvi to Iovance Biotherapeutics Inc.
The FDA granted the approval of Casgevy to Vertex Pharmaceuticals Inc., and Lyfgenia to Bluebird Bio Inc.
The FDA granted the approval of Ogsiveo to SpringWorks Therapeutics Inc.
Ixchiq is a single-dose, attenuated vaccine, safe to be administered to individuals above 18 years
The over-the-counter at-home COVID-19 test detects positive SARS-CoV-2 infection with 89.8 percent sensitivity
Adzynma safely and effectively “filled in” for the mutated ADAMTS13 enzyme in patients with cTTP
Wezlana has similar safety and efficacy as its reference product and is a cost-effective alternative for chronic inflammation
Tibsovo can be used with FDA-approved companion diagnostic RealTime IDH1 Assay to detect and treat MDS
Improved vaccine includes Omicron variant’s spike protein and can offer enhanced protection in the 2023–2024 flu season
The new prescription test doesn’t identify or evaluate all known genes that may predispose an individual to cancer
New rule could address the exponentially rising risks associated with most modern LDTs
Tyruko® has been shown to safely mitigate and manage inflammation in autoimmune conditions like Crohn’s disease
According to the CDC, RSV is the leading cause of infant hospitalization in the US and warrants immediate preventive action
Multicenter clinical trials demonstrated the efficacy of Zurzuvae in women with PPD
Beyfortus proved to be safe and efficacious in trials with infants at varying degrees of risk for RSV infection